Attention Deficit Hyperactivity Disorder (ADHD)

Pipeline Programs

Companies

Clinical Trials

3 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

PfizerNEW YORK, NY

1 program

methylphenidate HCl ERCTPhase 42 trials

Active Trials

NCT03580005Withdrawn0Est. Oct 2021

NCT03546400Withdrawn0Est. Dec 2020

Supernus PharmaceuticalsMD - Rockville

3 programs

SPN-810Phase 31 trial

Active Trials

NCT02618408Completed333Est. Oct 2019

NCT02691182Terminated491Est. May 2021

NCT02618434Completed297Est. Feb 2020

OtsukaJapan - Tokushima

2 programs

EB-1020Phase 31 trial

EB-1020Phase 2/31 trial

Active Trials

NCT06931080Recruiting630Est. Dec 2027

NCT06926829Recruiting180Est. Dec 2027

Purdue PharmaCT - Stamford

1 program

PRC-063 25 mgPhase 31 trial

Active Trials

NCT02225639Completed60Est. May 2015

Angeles TherapeuticsCA - Los Angeles

4 programs

Active TNSN/A1 trial

Active eTNSN/A1 trial

Behavioral assessment and NAT EEG testsN/A1 trial

Active Trials

NCT03870737Completed22Est. May 2018

NCT03888391Completed18Est. May 2018

NCT02155608Completed62Est. May 2018

+1 more trials

TakedaTOKYO, Japan

4 programs

Drug Use Study With Intuniv® in AustraliaN/A1 trial

SHP465PHASE_11 trial

SHP465 12.5mgPHASE_11 trial

SHP465PHASE_31 trial

Active Trials

NCT04866030Completed100Est. Aug 2021

NCT03327402Completed24Est. Oct 2018

NCT02578030Completed27Est. Nov 2015

+1 more trials

Human BioSciencesWV - Martinsburg

2 programs

FOCAL+N/A1 trial

IBBSN/A1 trial

Active Trials

NCT06960980Recruiting204Est. Aug 2029

NCT01542528Completed117Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

Pfizermethylphenidate HCl ERCT

OtsukaEB-1020

TakedaSHP465

Supernus PharmaceuticalsSPN-810

Purdue PharmaPRC-063 25 mg

OtsukaEB-1020

TakedaSHP465

TakedaSHP465 12.5mg

Human BioSciencesFOCAL+

TakedaDrug Use Study With Intuniv® in Australia

Angeles TherapeuticsActive eTNS

Angeles TherapeuticsActive TNS

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 2,786 patients across 18 trials

NCT03580005 Pfizermethylphenidate HCl ERCT

A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD.

Start: Oct 2018Est. completion: Oct 20210

Phase 4Withdrawn

NCT03546400 Pfizermethylphenidate HCl ERCT

Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.

Start: Sep 2018Est. completion: Dec 20200

Phase 4Withdrawn

NCT06926829 OtsukaEB-1020

A Long-term Trial of EB-1020 in Adult Patients With ADHD

Start: Jun 2025Est. completion: Dec 2027180 patients

Phase 3Recruiting

NCT03325894 TakedaSHP465

Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

Start: Jan 2018Est. completion: Jan 2019141 patients

Phase 3Terminated

NCT02691182 Supernus PharmaceuticalsSPN-810

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)

Start: Apr 2016Est. completion: May 2021491 patients

Phase 3Terminated

NCT02618434 Supernus PharmaceuticalsSPN-810

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Start: Feb 2016Est. completion: Feb 2020297 patients

Phase 3Completed

NCT02618408 Supernus PharmaceuticalsSPN-810

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)

Start: Jan 2016Est. completion: Oct 2019333 patients

Phase 3Completed

NCT02225639 Purdue PharmaPRC-063 25 mg

PRC-063 in an ADULT Workplace Environment

Start: Aug 2014Est. completion: May 201560 patients

Phase 3Completed

NCT06931080 OtsukaEB-1020

Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

Start: Apr 2025Est. completion: Dec 2027630 patients

Phase 2/3Recruiting

NCT03327402 TakedaSHP465

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start: Mar 2018Est. completion: Oct 201824 patients

Phase 1Completed

NCT02578030 TakedaSHP465 12.5mg

Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD

Start: Oct 2015Est. completion: Nov 201527 patients

Phase 1Completed

NCT06960980 Human BioSciencesFOCAL+

Improving ADHD Teen Driving - Virtual Reality

Start: Sep 2025Est. completion: Aug 2029204 patients

N/ARecruiting

NCT04866030 TakedaDrug Use Study With Intuniv® in Australia

Drug Use Study With Intuniv® in Australia

Start: Mar 2019Est. completion: Aug 2021100 patients

N/ACompleted

NCT02155608 Angeles TherapeuticsActive eTNS

Trigeminal Nerve Stimulation for ADHD

Start: Apr 2015Est. completion: May 201862 patients

N/ACompleted

NCT03870737 Angeles TherapeuticsActive TNS

Four-week Open-trial Extension TNS for ADHD

Start: Dec 2014Est. completion: May 201822 patients

N/ACompleted

NCT03888391 Angeles TherapeuticsActive TNS

12 Month Open Extension of TNS for ADHD.

Start: Dec 2014Est. completion: May 201818 patients

N/ACompleted

NCT02407496 Angeles TherapeuticsBehavioral assessment and NAT EEG tests

Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)

Start: Jun 2014Est. completion: Sep 201580 patients

N/ACompleted

NCT01542528 Human BioSciencesIBBS

Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)

Start: Mar 2012Est. completion: Jul 2016117 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals

3 actively recruiting trials targeting 2,786 patients

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.